About
Peptide Immunotherapy
Areas of Focus
Categories
Gene Therapy, RNA & Peptide Therapy
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
8
As Collaborator
0
Total Enrollment
1,080
By Phase
PHASE1: 1PHASE2: 6PHASE3: 1
By Status
COMPLETED: 5RECRUITING: 1ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06625710Lead Sponsor
Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects
PHASE1Recruiting
56 participants
Started: Oct 8, 2024 · Completed: Dec 30, 2025
NCT06235775Lead Sponsor
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
PHASE2Active, not recruiting
67 participants
Started: Dec 12, 2023 · Completed: Dec 31, 2025
NCT05819658Lead Sponsor
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
PHASE2Completed
78 participants
Started: Jun 14, 2023 · Completed: Oct 11, 2024
NCT05189210Lead Sponsor
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
PHASE2Completed
199 participants
Started: Oct 5, 2022 · Completed: Apr 16, 2025
NCT04032067Lead Sponsor
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
PHASE3Completed
423 participants
Started: Oct 30, 2019 · Completed: Mar 17, 2022
Locations (1)
Headquarters
Seongnam, Korea
Map
Loading map...